Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening

European Journal of Cancer Prevention

Volumn 22, Issue 4, 2013, Pages 305-310

  Tao, Sha ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

advanced colorectal adenoma; colorectal cancer; detection; faecal occult blood tests

Indexed keywords

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; OCCULT BLOOD; ROC CURVE;

EID: 84878878402     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32835b6991     Document Type: Article

References (23)

1. Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M (2006). Does a negative screening colonoscopy ever need to be repeated? Gut 55:1145-1150.
2. Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M (2007). Case- control study supports extension of surveillance interval after colonoscopic polypectomy to at least 5 yr. Am J Gastroenterol 102:1739-1744.
3. Brenner H, Haug U, Hundt S (2010a). Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. Int J Cancer 127:1643-1649.
4. Brenner H, Haug U, Hundt S (2010b). Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 105:2457-2464.
5. Brenner H, Tao S, Haug U (2010c). Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304:2513-2520.
6. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M (2011). Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 154:22-30.
7. Chen LS, Liao CS, Chang SH, Lai HC, Chen TH (2007). Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 14:191-199.
8. Fraser CG, Allison JE, Halloran SP, Young GP (2012). A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 104:810-814.
9. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, et al. (2007). Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56:210-214.
10. Haug U, Hundt S, Brenner H (2010). Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 105:682-690.
11. Hewitson P, Glasziou P,Watson E, Towler B, Irwig L (2008). Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103:1541-1549.
12. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, et al. (2009). Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 100:1103-1110.
13. Hundt S, Haug U, Brenner H (2009). Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 150:162-169.
14. Levi Z, Rozen P, Hazazi R, Vilkin A,Waked A, Maoz E, et al. (2007). A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 146:244-255.
15. McDonald PJ, Anderson CM, Fraser CG (2011). Acceptance quality checks for qualitative fecal immunochemical tests ensure screening program consistency. Int J Cancer 128:247-248, author reply 248-249.
16. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, et al. (2010). Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 105:2017-2025.
17. Park MJ, Choi KS, Lee YK, Jun JK, Lee HY (2012). A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program. Scand J Gastroenterol 47:461-466.
18. Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, et al. (2012). Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 26:131-147.
19. Rozen P, Liphshitz I, Barchana M (2012). Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations. Eur J Cancer Prev 21:247-253.
20. Tao S, Haug U, Kuhn K, Brenner H (2012). Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer 106: 1424-1430.
21. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. (2008). Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135:82-90.
22. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, et al. (2009). Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 101:1274-1281.
23. Van Rossum LG, van Rijn AF, Verbeek AL, van Oijen MG, Laheij RJ, Fockens P, et al. (2011). Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 128:1908-1917.